Which Small-Cap Value ETF Is Better: State Street's SLYV or iShares' ISCV?

The main implication is not “cheaper index fund wins,” but that ISCV’s broader, less filtered basket is a cleaner expression of a small-cap value rebound if rates stay sticky and cyclical breadth improves. Its higher breadth reduces single-name idiosyncrasy and should matter most in a regime where the market starts rewarding book/earnings mean reversion over balance-sheet quality. SLYV’s profitability screen likely improves downside behavior in true credit stress, but it also biases the fund toward higher-quality traps that can lag in sharp value rallies.

Second-order, the names embedded in ISCV tilt toward capital-intensity and commodity-adjacent cyclicals, which makes the ETF more sensitive to curve steepening and a better beneficiary if real yields drift lower over the next 3-6 months. That said, the presence of higher-velocity businesses like MRNA and MTCH alongside cyclicals means the basket is not a pure macro bet; it is a mixed factor sleeve where idiosyncratic catalysts can overwhelm the style exposure. The market is likely underappreciating how much the lower fee compounds over multi-year holding periods when the return differential is otherwise small.

The contrarian read is that SLYV’s recent relative strength may be partly a quality premium masquerading as better “value” exposure, especially after a period where profitability screens were rewarded. If macro growth rolls over or credit spreads widen, ISCV’s broader, deeper-value exposure should see higher dispersion but also more upside convexity on easing financial conditions. The key risk is that small-cap value leadership fails to broaden beyond a handful of balance-sheet survivors, in which case SLYV’s screen is worth paying for.